Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Wolff

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Muscle & Nerve|June 30, 2026
Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative StudyMeg Mendoza, Elena Wolff, Michael Chou, et al.
Clinical Pharmacology and Therapeutics|September 2, 2021
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug ReactionsLuis Correia Pinheiro, Thijs J Giezen, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
The Journal of Continuing Education in the Health Professions|March 29, 2023
Addressing the Mental Health Needs of Inmates Through Education for Correctional Officers-A Narrative ReviewShaheen A Darani, Robert McMaster, Elena Wolff, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2023
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, et al.
JBMR Plus|May 11, 2026
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosisRichard Eastell, Eric Orwoll, Felicia Cosman, et al.
ESMO Open|September 25, 2018
Preparing for the incoming wave of biosimilars in oncologyElena Wolff-Holz, Juan Garcia Burgos, Rosa Giuliani, et al.
Advances in Therapy|June 10, 2025
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for InterchangeabilitySarika Deodhar, Subramanian Loganathan, Ramesh Kadadanamari Subbarama Reddy, et al.
Annals of the New York Academy of Sciences|April 27, 2017
Equivalence of complex drug products: advances in and challenges for current regulatory frameworksLeonie Hussaarts, Stefan Mühlebach, Vinod P Shah, et al.
Expert Opinion on Biological Therapy|October 16, 2025
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trialJacek C Szepietowski, Adam Reich, Steven R Feldman, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Muscle & Nerve|June 30, 2026
Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative StudyMeg Mendoza, Elena Wolff, Michael Chou, et al.
Clinical Pharmacology and Therapeutics|September 2, 2021
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug ReactionsLuis Correia Pinheiro, Thijs J Giezen, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
The Journal of Continuing Education in the Health Professions|March 29, 2023
Addressing the Mental Health Needs of Inmates Through Education for Correctional Officers-A Narrative ReviewShaheen A Darani, Robert McMaster, Elena Wolff, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2023
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, et al.
JBMR Plus|May 11, 2026
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosisRichard Eastell, Eric Orwoll, Felicia Cosman, et al.
ESMO Open|September 25, 2018
Preparing for the incoming wave of biosimilars in oncologyElena Wolff-Holz, Juan Garcia Burgos, Rosa Giuliani, et al.
Advances in Therapy|June 10, 2025
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for InterchangeabilitySarika Deodhar, Subramanian Loganathan, Ramesh Kadadanamari Subbarama Reddy, et al.
Annals of the New York Academy of Sciences|April 27, 2017
Equivalence of complex drug products: advances in and challenges for current regulatory frameworksLeonie Hussaarts, Stefan Mühlebach, Vinod P Shah, et al.
Expert Opinion on Biological Therapy|October 16, 2025
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trialJacek C Szepietowski, Adam Reich, Steven R Feldman, et al.
Pageof 3